Table 2 Anti-VEGF biosimilars in developmenta.
Company | Compound name | Registered clinical trials | Phase |
|---|---|---|---|
Aflibercept biosimilars | |||
Amgen | ABP 938 | NCT04270747 | III |
Alteogen | ALT-L9 | NCT04058535 | I |
Coherus Biosciences | CHS-2020 | – | |
Formycon | FYB203 | NCT04522167 | III |
Momenta/Mylan | MYL-1701P | NCT03610646, NCT04674800 | III (both) |
Samsung Bioepis | SB15 | NCT04450329 | III |
Ranibizumab biosimilars | |||
Coherus Biosciences/Bioeq | FYB201 | NCT02611778 | III |
Lupin | LUBT010 | NCT04690556 | III |
Samsung Bioepis | SB11 | NCT03150589 | III |
Xbrane | Xlucane | NCT03805100 | III |
Bevacizumab biosimilars | |||
Outlook therapeutics | ONS-5010 | NCT03834753 | III |
Pfizer | Bevacizumab-bvzr/Zirabev | Currently only oncology indications | |
Amgen/Allergan | Bevacizumab-awwb/MVASI | Currently only oncology indications | |
